AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, developer of the MEVION S250 Proton Therapy System for cancer treatment. AMS owns an equity interest in Mevion, and will supply a MEVION S250 for the proton center now under construction at MD Anderson Cancer Center in Orlando, in addition to other projects under development: MEVION S250 at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Moves to Clinical Commissioning Littleton, MA, September 22nd, 2013 -- Today, Mevion Medical Systems announced moving from acceptance testing to the clinical commissioning phase of its MEVION S250 Proton Therapy System installed at the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO. The MEVION S250 is a unique proton therapy device designed to deliver the same precise, non-invasive treatment capabilities and advantages of conventional systems but with a significantly reduced size, improved reliability, efficient clinical workflow and lower implementation and operational costs. This important milestone marks the handover and operational control of the first MEVION S250 to the physics and radiation oncology proton teams from the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine for clinical commissioning and patient treatment. Acceptance testing is a series of demanding tests designed to independently put the MEVION S250 through its paces, carefully validating that technical and clinical performance specifications are met and that the system is ready for clinical commissioning. The Washington University physics team led by Eric E. Klein, PhD, chief of proton therapy physics, performed these tests over a three-month period. "The results of our testing confirm that the MEVION S250 is ready to move into the clinical commissioning phase," said Dr. Klein. "We are excited to be in final clinical preparation for our first patient treatment later this year," added Jeffrey D. Bradley, MD, Washington University radiation oncologist and director of the S. Lee Kling Center for Proton Therapy.